145
Participants
Start Date
February 1, 2023
Primary Completion Date
November 1, 2025
Study Completion Date
June 1, 2027
Apatinib
TKI
Dalpiciclib
CDK4/6 inhibitor
Fulvestrant/AI
Endocrine therapy
RECRUITING
Breast cancer institute of Fudan University Cancer Hospital, Shanghai
Peking University Cancer Hospital & Institute
OTHER
First Hospital of China Medical University
OTHER
Sun Yat-sen University
OTHER
First Affiliated Hospital Xi'an Jiaotong University
OTHER
Liaoning Cancer Hospital & Institute
OTHER
Chongqing University Cancer Hospital
OTHER
Northern Jiangsu People's Hospital
OTHER
Fujian Medical University Union Hospital
OTHER
Ningbo Medical Center Lihuili Hospital
OTHER_GOV
Shanghai First Maternity and Infant Hospital
OTHER
Shanghai 6th People's Hospital
OTHER
Affiliated Hospital of Nantong University
OTHER
Fudan University
OTHER